Skip to main content

PK in Healthy Volunteers

0
Pipeline Programs
2
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 1 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Sanofi
SanofiPARIS, France
1 program
FexinidazolePHASE_1Small Molecule3 trials
Active Trials
NCT05607173Completed21Est. May 2023
NCT03025789Completed174Est. Feb 2021
NCT01340157Completed12Est. Apr 2011
PharmaEssentia
PharmaEssentiaMA - Burlington
1 program
PEG-MetHuG-CSFPHASE_11 trial
Active Trials
NCT06698861Completed30Est. Feb 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SanofiFexinidazole
PharmaEssentiaPEG-MetHuG-CSF
SanofiFexinidazole
SanofiFexinidazole

Clinical Trials (4)

Total enrollment: 237 patients across 4 trials

NCT03025789SanofiFexinidazole

Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage

Start: Nov 2016Est. completion: Feb 2021174 patients
Phase 3Completed

A Phase I PK/PD Study of PEG-MetHuG-CSF (P2203) in Healthy Volunteers

Start: Aug 2024Est. completion: Feb 202530 patients
Phase 1Completed
NCT05607173SanofiFexinidazole

A Pharmacokinetic and Tolerability Study of Fexinidazole in a Single Oral Dose in Adult Participants With Mild and Moderate Hepatic Impairment

Start: Jan 2023Est. completion: May 202321 patients
Phase 1Completed
NCT01340157SanofiFexinidazole

Fexinidazole (1200mg) Bioavailability Under Different Food Intake Conditions

Start: Feb 2011Est. completion: Apr 201112 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

Small Molecule is the dominant modality (100% of programs)
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.